Urinary Metabolite Risk Biomarkers of Lung Cancer: A Prospective Cohort Study

Background: Lung cancer is a major health burden causing 160,000 and 1.6 million deaths annually in the United States and worldwide, respectively. Methods: While seeking to identify stable and reproducible biomarkers in noninvasively collected biofluids, we assessed whether previously identified metabolite urinary lung cancer biomarkers, creatine riboside (CR), N-acetylneuraminic acid (NANA), cortisol sulfate, and indeterminate metabolite 561+, were elevated in the urines of subjects prior to lung cancer diagnosis in a well-characterized prospective Southern Community Cohort Study (SCCS). Urine was examined from 178 patients and 351 nondiseased controls, confirming that one of four metabolites was associated with lung cancer risk in the overall case–control set, whereas two metabolites were associated with lung cancer risk in European-Americans. Results: OR of lung cancer associated with elevated CR levels, and adjusted for smoking and other potential confounders, was 2.0 [95% confidence interval (CI), 1.2–3.4; P= 0.01]. In European-Americans, both CR and NANA were significantly associated with lung cancer risk (OR = 5.3; 95% CI, 1.6–17.6; P= 0.006 and OR=3.5; 95% CI, 1.5–8.4; P= 0.004, respectively). However, race itself did not significantly modify the associations. ROC analysis showed that adding CR and NANA to a model containing previously established lung cancer risk factors led to a significantly improved classifier (P= 0.01). Increasing urinary levels of CR and NANA displayed a positive association with increasing tumor size, strengthening a previously established link to altered tumor metabolism. Conclusion and Impact: These replicated results provide evidence that identified urinary metabolite biomarkers have a potential utility as noninvasive, clinical screening tools for early diagnosis of lung cancer. Cancer Epidemiol Biomarkers Prev; 25(6); 978–86. ©2016 AACR.

[1]  J. Mulshine,et al.  Lung cancer screening guidelines: common ground and differences. , 2014, Translational lung cancer research.

[2]  D. Wood,et al.  The importance of lung cancer screening with low-dose computed tomography for Medicare beneficiaries. , 2014, JAMA internal medicine.

[3]  Deepa Naishadham,et al.  Cancer statistics for African Americans, 2013 , 2013, CA: a cancer journal for clinicians.

[4]  Leah E. Mechanic,et al.  Lung cancer survival and functional polymorphisms in MBL2, an innate-immunity gene. , 2007, Journal of the National Cancer Institute.

[5]  M S Pepe,et al.  Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.

[6]  Timothy R Church,et al.  Selection criteria for lung-cancer screening. , 2013, The New England journal of medicine.

[7]  C. Boring,et al.  Cancer statistics for african americans , 1992, CA: a cancer journal for clinicians.

[8]  H. Dienemann,et al.  Non-small cell lung cancer is characterized by dramatic changes in phospholipid profiles , 2015, International journal of cancer.

[9]  Fabian J Theis,et al.  Effects of smoking and smoking cessation on human serum metabolite profile: results from the KORA cohort study , 2013, BMC Medicine.

[10]  Sharon S. Hori,et al.  Detecting cancers through tumor-activatable minicircles that lead to a detectable blood biomarker , 2015, Proceedings of the National Academy of Sciences.

[11]  C. Gatsonis,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[12]  J. Phillips,et al.  Glycosylation alterations in lung and brain cancer. , 2015, Advances in cancer research.

[13]  P. Pinsky,et al.  Short- and Long-term Lung Cancer Risk Associated with Noncalcified Nodules Observed on Low-Dose CT , 2014, Cancer Prevention Research.

[14]  L. Signorello,et al.  Lung cancer risk among smokers of menthol cigarettes. , 2011, Journal of the National Cancer Institute.

[15]  Emmanuel Hatzakis,et al.  Noninvasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer. , 2014, Cancer research.

[16]  F. Bray,et al.  International lung cancer trends by histologic type: Male:Female differences diminishing and adenocarcinoma rates rising , 2005, International journal of cancer.

[17]  Dong Liang,et al.  The Ability of Bilirubin in Identifying Smokers with Higher Risk of Lung Cancer: A Large Cohort Study in Conjunction with Global Metabolomic Profiling , 2014, Clinical Cancer Research.

[18]  R. Peto,et al.  Serum Cotinine Level as Predictor of Lung Cancer Risk , 2006, Cancer Epidemiology Biomarkers & Prevention.

[19]  Oliver Fiehn,et al.  Metabolomic Markers of Altered Nucleotide Metabolism in Early Stage Adenocarcinoma , 2015, Cancer Prevention Research.

[20]  Jian-Min Yuan,et al.  Urinary metabolites of a polycyclic aromatic hydrocarbon and volatile organic compounds in relation to lung cancer development in lifelong never smokers in the Shanghai Cohort Study. , 2014, Carcinogenesis.

[21]  J. Cuzick.  A Wilcoxon-type test for trend. , 1985, Statistics in medicine.

[22]  Heber MacMahon,et al.  The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. , 2012, The Journal of thoracic and cardiovascular surgery.

[23]  L. Le Marchand,et al.  Variation in Levels of the Lung Carcinogen NNAL and Its Glucuronides in the Urine of Cigarette Smokers from Five Ethnic Groups with Differing Risks for Lung Cancer , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[24]  J. Samet,et al.  Menthol Cigarettes, Race/Ethnicity, and Biomarkers of Tobacco Use in U.S. Adults: The 1999–2010 National Health and Nutrition Examination Survey (NHANES) , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[25]  R. Schauer.  Sialic acids: fascinating sugars in higher animals and man. , 2004, Zoology.

[26]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[27]  Charles Maynard,et al.  A primer and comparative review of major US mortality databases. , 2002, Annals of epidemiology.

[28]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.

[29]  D. Wood,et al.  Expert opinion: United States Preventive Services Task Force recommendation on screening for lung cancer. , 2014, Journal of thoracic imaging.

[30]  Jian-Min Yuan,et al.  Urinary levels of tobacco-specific nitrosamine metabolites in relation to lung cancer development in two prospective cohorts of cigarette smokers. , 2009, Cancer research.

[31]  Leah E. Mechanic,et al.  Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. , 2011, Journal of the National Cancer Institute.

[32]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[33]  A. Jemal,et al.  Prevalence of Major Risk Factors and Use of Screening Tests for Cancer in the United States , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[34]  K. Rabe,et al.  Management of non-small-cell lung cancer: recent developments , 2013, The Lancet.

[35]  N. Benowitz,et al.  Racial differences in the relationship between number of cigarettes smoked and nicotine and carcinogen exposure. , 2011, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[36]  Zhidong Liu,et al.  Methods for detection of circulating cells in non-small cell lung cancer. , 2014, Frontiers in bioscience.

[37]  Rongwei Fu,et al.  Screening for Lung Cancer With Low-Dose Computed Tomography: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendation , 2013, Annals of Internal Medicine.

[38]  William Hazelton,et al.  Benefits and Harms of Computed Tomography Lung Cancer Screening Strategies: A Comparative Modeling Study for the U.S. Preventive Services Task Force , 2014, Annals of Internal Medicine.

[39]  Edward J Park,et al.  Detection and isolation of circulating tumor cells: principles and methods. , 2013, Biotechnology advances.

[40]  B. Henderson,et al.  Racial/Ethnic Differences in Postmenopausal Endogenous Hormones: The Multiethnic Cohort Study , 2006, Cancer Epidemiology Biomarkers & Prevention.

[41]  P. Massion,et al.  The State of Molecular Biomarkers for the Early Detection of Lung Cancer , 2012, Cancer Prevention Research.

[42]  A. Lokshin,et al.  Urinary Protein Biomarkers in the Early Detection of Lung Cancer , 2014, Cancer Prevention Research.

[43]  Klaus Pantel,et al.  [The circulating tumor cells: liquid biopsy of cancer]. , 2014, Klinicheskaia laboratornaia diagnostika.

[44]  T. Friedlander,et al.  Looking back, to the future of circulating tumor cells. , 2014, Pharmacology & therapeutics.

[45]  Mahesh J. Patel,et al.  Race and sex differences in small-molecule metabolites and metabolic hormones in overweight and obese adults. , 2013, Omics : a journal of integrative biology.

[46]  W. Huebner,et al.  Strategies for using the National Death Index and the Social Security Administration for death ascertainment in large occupational cohort mortality studies. , 2010, American journal of epidemiology.

[47]  C. Preininger,et al.  Bladder cancer biomarker array to detect aberrant levels of proteins in urine. , 2015, The Analyst.